Clinical Trial Update: Molecular and Cellular Mechanism in Rhinitis Allergic Patients Treated With GRAZAX® [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial update on molecular and cellular mechanisms in allergic rhinitis patients treated with GRAZAX.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis
• Allergic Rhinoconjunctivitis

Drugs mentioned

• GRAZAX (birch pollen sublingual immunotherapy tablet)

Snippet

Sponsor: ALK-Abelló A/S | Conditions: Allergic Rhinoconjunctivitis | Phase 4 | Status: COMPLETED